Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619001708145
Ethics application status
Approved
Date submitted
30/06/2019
Date registered
4/12/2019
Date last updated
4/12/2019
Date data sharing statement initially provided
4/12/2019
Type of registration
Retrospectively registered
Titles & IDs
Public title
Randomized controlled trial (RCT) comparing between High versus Standard dose caffeine citrate for apnoea in prematurity
Query!
Scientific title
Randomized controlled trial (RCT) comparing between High versus Standard dose caffeine citrate for apnoea in prematurity for premature baby with gestational age 28 to 32 weeks.
Query!
Secondary ID [1]
298211
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Apnoea of prematurity
312808
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
313050
313050
0
0
Query!
Complications of newborn
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Name : Comparing between High dose caffeine (Arm 1) and standard dose caffeine (Arm 2)
Why : Available literatures regarding high versus standard/low dose caffeine for Apnoea in prematurity is not conclusive due to heterogeneity of the doses, gestational age, indication of starting caffeine and sample size. However, some data suggest that the high dose caffeine is beneficial without causing adverse effects except for mild tachycardia. The reason of conducting the study is to determine the efficacy and safety of a high dose of caffeine compared to standard dose for the prevention of apnoea in prematurity
WHAT
Materials : All the research tools that will be used in the study is routinely used for premature babies in Neonatal Intensive Care Unit (NICU). All the research tools have been proved its safety and reliability. Infant’s oxygen saturation, heart rate, and respiratory rate are continuously monitored using monitor that is available in NICU. Blood pressure will be checked, indirectly by oscillometry or Intra-arterial blood pressure if patient is on arterial line.
Procedures :
Before premature delivery and subject recruitment, medical officer or specialist will be subjected to do prenatal counselling to the mothers in antenatal ward HUSM. During the counselling, the study will be briefly explained to the mother in order to give them an ample time to think whether wants to include in the study or not.
Premature babies who fulfill inclusion and exclusion criteria will be assigned randomly into either two groups (Group A: High dose group, Group B: Standard dose group). Infants in group A will receive high dose oral caffeine citrate (loading dose of 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance dose of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base). Maintenance dose will be given 24 hours after loading. Infants in group B will receive standard dose oral caffeine citrate (loading dose of 20 mg/kg/day equivalent to 10mg/kg/day of caffeine base and maintenance dose of 10mg/kg/day equivalent to 5 mg/kg/day of caffeine base)
Oral caffeine loading dose will be given to the allocation group (Group A and Group B) within 24 hours periextubation period. If the patient is not intubated, oral caffeine loading dose will be given immediately. If patient has failure extubation, caffeine will be off and continue ventilation. Sameh Mohammed et al defined failure extubation as requiring reintubation within 72 hours. If successful extubation, maintenance dose (MD) will be continued 24 hours after starting caffeine and continue on daily basis. If patient has feeding intolerance while the patient is on caffeine, the medication will be changed into intravenous aminophylline. Previous oral caffeine dose will be restarted once feeding intolerance resolved.
The duration of oral caffeine will be continued at least corrected gestational age is 34 weeks after been assessed by trained doctor. Oral caffeine will be continued beyond 34 weeks gestational age if indicated and assigned by doctor.
The study will be conducted in Neonatal Intensive Care Unit, Hospital USM, Kubang Kerian Kelantan,Malaysia. The hospital is a teaching hospital for University Sains Malaysia and this is where the Health Campus located. Kubang Kerian is one of the major towns of Kelantan, a state in Malaysia where majority of its population are Malays from different socio-economic background. The Neonatal Intensive Care Unit provides level 1 to level 4 intensive care to neonate patient and received referral from all parts of Kelantan and all over the country
The Primary Investigator will monitor the study monthly and fill the data in proforma.
Query!
Intervention code [1]
314470
0
Treatment: Drugs
Query!
Comparator / control treatment
Infants in group A / control group, received high dose oral caffeine citrate (loading dose of 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance dose of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base). Maintenance dose will be given 24 hours after loading
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
320057
0
frequency of apnoea per duration of treatment in prematurity between high versus standard dose of caffeine as assessed by clinical examination
Participants will be examined by specialist and senior registrar every day during the duration of treatment
Equipment that will be used for clinical examination are stethoscope, BP oscillatory monitoring, intraarterial BP if participant is on arterial line, SPO2 monitoring. All equipment used is routinely available in NICU.
Query!
Assessment method [1]
320057
0
Query!
Timepoint [1]
320057
0
every day after starting on syrup caffeine until or beyond 34 weeks gestation as long as patient is on the treatment
Query!
Primary outcome [2]
321602
0
total number of days of apnoea in prematurity between high versus standard dose of caffeine as assessed by clinal examination
Participants will be examined by specialist and senior registrar every day during the duration of treatment
Equipment that will be used for clinical examination are stethoscope, BP oscillatory monitoring, intraarterial BP if participant is on arterial line, SPO2 monitoring. All equipment used is routinely available in NICU.
Query!
Assessment method [2]
321602
0
Query!
Timepoint [2]
321602
0
every day after starting on first dose of oral caffeine until or beyond 34 weeks gestational age as long as patient is on caffeine treatment
Query!
Secondary outcome [1]
370383
0
Extubation failure as assessed by clinical examination
Participants will be examined by specialist and senior registrar every day during the duration of treatment
Equipment that will be used for clinical examination are stethoscope, BP oscillatory monitoring, intraarterial BP if participant is on arterial line, SPO2 monitoring. All equipment used is routinely available in NICU.
Query!
Assessment method [1]
370383
0
Query!
Timepoint [1]
370383
0
assess after patient's extubation . Extubation failure defined as requiring reintubation within 72 hours extubation period
Participant will be closely monitored within 72 hours post extubation
Query!
Secondary outcome [2]
375553
0
Duration of Non Invasive ventilation. How many days / months the patient require on Non Invasive ventilation (e.g: Duopap, Cpap, optiflow). The outcome will be assessed by using data-linkage to medical records
Query!
Assessment method [2]
375553
0
Query!
Timepoint [2]
375553
0
assess after patient has successful extubation
Query!
Secondary outcome [3]
375554
0
Duration of Patient is on nasal prong oxygen as assessed by clinical examination
How many days/months the participant is on nasal prong oxygen
Query!
Assessment method [3]
375554
0
Query!
Timepoint [3]
375554
0
assess the duration while patient is on nasal prong oxygen
Query!
Secondary outcome [4]
375555
0
Chronic lung disease as assessed by clinical examination and chest x- ray
Query!
Assessment method [4]
375555
0
Query!
Timepoint [4]
375555
0
Assess once patient is at corrected gestational age 36 weeks or discharge , which one is earlier as long as patient is on oxygen usage at least 28 days.
Query!
Secondary outcome [5]
375556
0
Post natal steroid therapy for Chronic Lung Disease assessed by clinical examination
If participant fulfilled criteria of Bronchopulmonary Dysplasia according to the National Institute of Child Health and Human Development diagnostic criteria , The clinician will start on post natal steroid therapy
Query!
Assessment method [5]
375556
0
Query!
Timepoint [5]
375556
0
Assess by neonatologist on steroid requirement once patient use oxygen at least 28 days
Query!
Secondary outcome [6]
375558
0
Retinopathy of prematurity assessed by ophthalmologist
Query!
Assessment method [6]
375558
0
Query!
Timepoint [6]
375558
0
Formal eye assessment done by ophthalmologist at 34 weeks gestational age
Query!
Secondary outcome [7]
375559
0
Intraventricular Hemorrhage (IVH) as assessed by doing ultrasound of cranium
Query!
Assessment method [7]
375559
0
Query!
Timepoint [7]
375559
0
Ultrasound of cranium will be done to all premature baby based on the protocol timing
Protocol timing :
Ist ultrasond cranium: Day 3 to Day 7
Second ultrasound cranium : Day 7 or Day 14 if no IVH
Weekly monitor with ultrasound cranium if presence of IVH
Query!
Secondary outcome [8]
375560
0
Tachycardia will be continuously monitored by trained medical staff . It will be assessed by using bench-top sphygmomanometer or machine monitoring if patient is on intraarterial line
Query!
Assessment method [8]
375560
0
Query!
Timepoint [8]
375560
0
continuous monitoring will be done throughout the treatment
Query!
Secondary outcome [9]
375561
0
weight monitoring by weigh scale
Query!
Assessment method [9]
375561
0
Query!
Timepoint [9]
375561
0
weight monitoring will be done twice weekly until discharge
Query!
Secondary outcome [10]
375562
0
urine electrolytes (urine calcium, urine phosphate and urine creatinine). This is composite outcome
Query!
Assessment method [10]
375562
0
Query!
Timepoint [10]
375562
0
urine electrolytes will be done at Day seven of treatment
Query!
Secondary outcome [11]
377193
0
Periventricular malacia as assessed by doing ultrasound cranium
Query!
Assessment method [11]
377193
0
Query!
Timepoint [11]
377193
0
Ultrasound of cranium will be done to all premature baby based on the protocol timing
Protocol timing :
Ist ultrasond cranium: Day 3 to Day 7
Second ultrasound cranium : Day 7 or Day 14 if no IVH
Weekly monitor with
ultrasound cranium if presence
of IVH
Query!
Secondary outcome [12]
377194
0
Hypertension will be continuously monitored by trained medical staff . It will be assessed by using bench-top sphygmomanometer
Query!
Assessment method [12]
377194
0
Query!
Timepoint [12]
377194
0
continous monitoring will be done throughout the treatment
Query!
Eligibility
Key inclusion criteria
1. Prematurity 26 to 32 completed weeks admitted to Neonatal Intensive Care Unit Hospital
Universiti Sains Malaysia
2. 24 hours periextubation period if ventilated
Query!
Minimum age
1
Hours
Query!
Query!
Maximum age
34
Weeks
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Hydrops fetalis
2. Major congenital anomaly (Major malformations causing significant functional or
cosmetic impairment or being life-limiting. ‘Examples of major malformations include
neural tube defect, hypoplastic left heart, ventral wall defect, and craniofacial cleft’)
3. Major neurological condition; examples Grade 3 or 4 intraventricular haemorrhage
4. Contraindication on starting oral medication (Examples Necrotising Enterocolitis,
bowel pathology like malrotation, Hirschprung disease)
Withdrawal criteria
1. Premature baby who developed Supraventricular tachycardia (SVT) or persistent
tachycardia during the course of treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/06/2019
Query!
Date of last participant enrolment
Anticipated
31/05/2020
Query!
Actual
Query!
Date of last data collection
Anticipated
14/06/2020
Query!
Actual
Query!
Sample size
Target
78
Query!
Accrual to date
3
Query!
Final
Query!
Recruitment outside Australia
Country [1]
21482
0
Malaysia
Query!
State/province [1]
21482
0
Kota Bharu, Kelantan
Query!
Funding & Sponsors
Funding source category [1]
302753
0
University
Query!
Name [1]
302753
0
Hospital Universiti Sains Malaysia
Query!
Address [1]
302753
0
Jalan Raja Perempuan Zainab II, Kubang Kerian, 16150 Kota Bharu, Kelantan
Query!
Country [1]
302753
0
Malaysia
Query!
Primary sponsor type
University
Query!
Name
Hospital Universiti Sains Malaysia
Query!
Address
Jalan Raja Perempuan Zainab II, Kubang Kerian, 16150 Kota Bharu, Kelantan
Query!
Country
Malaysia
Query!
Secondary sponsor category [1]
302689
0
None
Query!
Name [1]
302689
0
Query!
Address [1]
302689
0
Query!
Country [1]
302689
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
303353
0
Jawatankuasa Etika Penyelidikan Manusia USM (JEPeM)
Query!
Ethics committee address [1]
303353
0
Universiti Sains Malaysia , Kampus Kesihatan,
16150 Kubang Kerian,Kelantan Malaysia
Query!
Ethics committee country [1]
303353
0
Malaysia
Query!
Date submitted for ethics approval [1]
303353
0
Query!
Approval date [1]
303353
0
24/03/2019
Query!
Ethics approval number [1]
303353
0
Query!
Summary
Brief summary
Study on Randomized Controlled Trial comparing high versus standard dose caffeine for apnoea in prematurity will be conducted in Hospital Universiti Sains Malaysia,Malaysia
The main purpose of conducting the study is to determine the optimum dose of caffeine for apnoea in prematurity.
The study hypothesize that high dose caffeine significantly reduce the number of apnoea in prematurity without significantly causing side effects.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
93378
0
Dr Anis Munirah Mohd Kori
Query!
Address
93378
0
Lot 119 Kampung Sungai Baru, Pengkalan Chepa, 16100 Kota Bharu, Kelantan, Malaysia
Hospital Universiti Sains Malaysia,16150 Kubang Kerian, Kalantan,Malaysia
Query!
Country
93378
0
Malaysia
Query!
Phone
93378
0
+60132076730
Query!
Fax
93378
0
Query!
Email
93378
0
[email protected]
Query!
Contact person for public queries
Name
93379
0
Dr Anis Munirah Mohd Kori
Query!
Address
93379
0
Lot 119 Kampung Sungai Baru, Pengkalan Chepa, 16100 Kota Bharu, Kelantan, Malaysia
Hospital Universiti Sains Malaysia,16150 Kubang Kerian, Kalantan,Malaysia
Query!
Country
93379
0
Malaysia
Query!
Phone
93379
0
+60132076730
Query!
Fax
93379
0
Query!
Email
93379
0
[email protected]
Query!
Contact person for scientific queries
Name
93380
0
Dr Anis Munirah Mohd Kori
Query!
Address
93380
0
Lot 119 Kampung Sungai Baru, Pengkalan Chepa, 16100 Kota Bharu, Kelantan, Malaysia
Hospital Universiti Sains Malaysia,16150 Kubang Kerian, Kalantan,Malaysia
Query!
Country
93380
0
Malaysia
Query!
Phone
93380
0
+60132076730
Query!
Fax
93380
0
Query!
Email
93380
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
2667
Study protocol
377580-(Uploaded-30-06-2019-23-49-23)-Study-related document.docx
2669
Informed consent form
377580-(Uploaded-30-06-2019-23-50-24)-Study-related document.docx
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF